Compare HFFG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | CGEN |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | Israel |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 148.7M |
| IPO Year | 2016 | 2001 |
| Metric | HFFG | CGEN |
|---|---|---|
| Price | $2.10 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 215.1K | ★ 286.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,201,667,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | $58.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $1.38 | $1.13 |
| 52 Week High | $4.93 | $2.38 |
| Indicator | HFFG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 60.79 |
| Support Level | $1.38 | $1.43 |
| Resistance Level | $2.37 | $2.38 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 81.82 | 61.79 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.